ABSTRACT
Traditionally lymphomas are classified into Hodgkin's disease [HD] and Non Hodgkin's lymphoma [NHL] depending upon histo-pathological evidence on biopsy taken from an enlarged lymph node. Delayed diagnosis in lymphoma deteriorates the health eminence resulting in poor outcome. The aim of the study is to estimate the incidence and clinical presentation of malignant lymphomas in Balochistan. Prospective Study. This study was carried in the Department of Radiotherapy and Oncology, Bolan Medical Complex Hospital, Quetta from June, 2006 to May, 2012. A total of 263 newly diagnosed patients of both types of lymphoma from different parts of Balochistan were registered in Bolan Medical Complex Hospital in Department of Radiotherapy and Oncology. Followed by histopathology, WHO classification and Ann Arbor staging was done to assign subtype and extent of disease. It was found that the incidence of Non Hodgkin's lymphoma a [64.7%] was greater than Hodgkin's disease [35.2%] and both present bimodal distribution in age. Male patients dominate female patients in both cases [2.5:1]. Lymph-adenopathy of cervical region was primary site in 44 % of cases while 27.6 % were extra nodal. Histopathology shows 57.4 % mixed cellularity variant in Hodgkin's lymphoma and 25.5% diffuse B cell pattern in Non Hodgkin's lymphoma. Ann Arbor staging reveals that 3.4% cases present with stage I and 64.5% show stage IV. To conclude Non Hodgkin's lymphoma is two times more frequent than Hodgkin's lymphoma with greater male contribution. Due to delayed diagnosis resulted in late stage presentation ,health awareness is needed for physicians and general population for availability of patients at a due time for management
ABSTRACT
Plasmacytoma is a rare B- lymphocyte neoplastic disorder that usually presents as the generalized disease multiple myeloma. Less than 5% of cases present as a solitary mass of monoclonal plasma cells in the bone or soft tissue. Although solitary osseous Plasmacytoma may arise in any bone, while Sternal involvement is uncommon. We report here a case of solitary plasmacytoma of sternum in a 55 years old male patient without signs and symptoms suggestive of multiple myeloma. Patient was treated with radiation therapy with a dosage of 40 Gy in 20 fractions
ABSTRACT
Aims and Objectives: A retrospective study of allcancer registered cases at the Center for NuclearMedicine and Radiotherapy [CENAR] Quetta From1st Jan, 1998 to 31st December 2009[12 Years] wascarried out. CENAR Quetta is the only cancermanagement center in Balochistan. The aim of thisanalysis was to highlight the prevalence of Cancerin Balochistan
Study Design: A retrospectivestudy
Place and duration of Study: The study wasconducted at CENAR Quetta
Results: During thestudy period, 12022 cancer patients were registeredat CENAR and BMCH Quetta. Out of these 10924files of patients [91.19%] were analyzed. The datawere analyzed from various angles of prevalencee.g. total number of registered cancer patients, Sex,Age, Histopathology, Demographic profile etc
Conclusion: As cancer management is a globalchallenging health problem including Pakistan, sothe first step for all health program worldwide is tohighlight the prevalence, incidence and etiologicalfactors of the disease in the locality, for step wisegoing towards management and control
ABSTRACT
Primary ovarian lymphoma presenting with ovarianmass as a primary disease is extremely rare. Wereport here a case of primary ovarian B-cell non-Hodgkin's lymphoma with bilateral involvementwhich was managed by surgery and chemotherapy.A 35 years old woman was admitted with signs andsymptoms suggestive of ovarian cancer. Thediagnosis of malignant lymphoma was establishedafter bilateral adnexectomy, histological andimmunohistochemical study of the excised tissue.The stage was I ES according to Ann-Arbor stagingsystem. The patient was planned for R-CHOPchemotherapy, but due to unaffordbility patient wastreated with 06 cycles of standard CHOP regimenand had completed her treatment. She has now beenon follow-up and is without disease from 15 monthsof treatment